标题
Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date
作者
关键词
-
出版物
Drug Design Development and Therapy
Volume Volume 15, Issue -, Pages 2815-2830
出版商
Informa UK Limited
发表日期
2021-06-28
DOI
10.2147/dddt.s281639
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
- (2021) C. D. Tweed et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
- (2020) Francesca Conradie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering
- (2020) Brendon M. Lee et al. PLoS Pathogens
- Evaluation of pharmacokinetic‐pharmacodynamic relationships and selection of drug combinations for tuberculosis
- (2020) Morris Muliaditan et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid
- (2020) Suha Kadura et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic Bacteria
- (2020) Zhijun Zhuang et al. MOLECULES
- Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from Mycobacterium tuberculosis
- (2020) Fuzhen Zhang et al. Infection and Drug Resistance
- Tuberculosis in Pregnancy
- (2020) Kathryn Miele et al. OBSTETRICS AND GYNECOLOGY
- The Clinical Dose of Pretomanid: An Exposure-Response Perspective
- (2020) Jerry R. Nedelman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis
- (2020) Dalin Rifat et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Building Optimal Three-Drug Combination Chemotherapy Regimens
- (2020) G. L. Drusano et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy
- (2020) Sedona Sweeney et al. BMJ Open
- Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis
- (2020) Elisa H. Ignatius et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update
- (2020) Fuad Mirzayev et al. EUROPEAN RESPIRATORY JOURNAL
- Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis
- (2019) Shu’an Wen et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Long-Term Effects on QT prolongation of Pretomanid, Alone and in Combinations, in Patients with Tuberculosis
- (2019) Hanbin Li et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- An overview of new antitubercular drugs, drug candidates, and their targets
- (2019) Aparna Bahuguna et al. MEDICINAL RESEARCH REVIEWS
- A revised biosynthetic pathway for the cofactor F420 in prokaryotes
- (2019) Ghader Bashiri et al. Nature Communications
- Nitroimidazole-containing compounds and their antibacterial and antitubercular activities
- (2019) Jingyu Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
- (2019) Conor D Tweed et al. Lancet Respiratory Medicine
- Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients
- (2018) Michael A. Lyons ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis
- (2018) K E Stott et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Drug–Drug Interactions Between PA-824 and Darunavir Based on Pharmacokinetics in Rats by LC–MS-MS
- (2018) Libin Wang et al. JOURNAL OF CHROMATOGRAPHIC SCIENCE
- Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis
- (2018) Mamoru Fujiwara et al. TUBERCULOSIS
- Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)
- (2018) Rafael Baptista et al. Scientific Reports
- A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs
- (2018) Alper Daskapan et al. CLINICAL PHARMACOKINETICS
- Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid
- (2017) Andrew M. Thompson et al. ACS Medicinal Chemistry Letters
- Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis
- (2016) Gaëlle Guiewi Makafe et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline
- (2015) Andreas H. Diacon et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Mutations in the Bacterial Ribosomal Protein L3 and Their Association with Antibiotic Resistance
- (2015) Rasmus N. Klitgaard et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutations in Genes for the F420Biosynthetic Pathway and a Nitroreductase Enzyme Are the Primary Resistance Determinants in SpontaneousIn Vitro-Selected PA-824-Resistant Mutants of Mycobacterium tuberculosis
- (2015) Hana L. Haver et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
- (2015) Rodney Dawson et al. LANCET
- Tissue distribution of pretomanid in rat brain via mass spectrometry imaging
- (2015) Adeola Shobo et al. XENOBIOTICA
- Novel Regimens Identified in Mice for Treatment of Latent Tuberculosis Infection in Contacts of Patients with Multidrug-Resistant Tuberculosis
- (2014) Jean-Philippe Lanoix et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroandIn VivoActivities of the Nitroimidazole TBA-354 against Mycobacterium tuberculosis
- (2014) A. M. Upton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin
- (2014) Kelly E. Dooley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mechanism of Action of 5-Nitrothiophenes against Mycobacterium tuberculosis
- (2014) R. C. Hartkoorn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Contribution of the Nitroimidazoles PA-824 and TBA-354 to the Activity of Novel Regimens in Murine Models of Tuberculosis
- (2014) Rokeya Tasneen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice
- (2014) Noton K. Dutta et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- LC–MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study
- (2014) Libin Wang et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Evaluation of Pharmacokinetic Interaction between PA-824 and Midazolam in Healthy Adult Subjects
- (2013) Helen Winter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Potent Rifamycin-Sparing Regimen Cures Guinea Pig Tuberculosis as Rapidly as the Standard Regimen
- (2013) Noton K. Dutta et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of a High-Calorie, High-Fat Meal on the Bioavailability and Pharmacokinetics of PA-824 in Healthy Adult Subjects
- (2013) Helen Winter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis
- (2013) M. McGrath et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Rv0132c of Mycobacterium tuberculosis Encodes a Coenzyme F420-Dependent Hydroxymycolic Acid Dehydrogenase
- (2013) Endang Purwantini et al. PLoS One
- Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824
- (2012) Andreas H. Diacon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
- (2012) Andreas H Diacon et al. LANCET
- A novel F420-dependent anti-oxidant mechanism protectsMycobacterium tuberculosisagainst oxidative stress and bactericidal agents
- (2012) Meera Gurumurthy et al. MOLECULAR MICROBIOLOGY
- Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis
- (2012) Scott G. Franzblau et al. TUBERCULOSIS
- Global Assessment of Genomic Regions Required for Growth in Mycobacterium tuberculosis
- (2012) Yanjia J. Zhang et al. PLoS Pathogens
- Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic Lesions
- (2011) Jamie Harper et al. JOURNAL OF INFECTIOUS DISEASES
- PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis
- (2010) Zahoor Ahmad et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Genetic Requirements for the Survival of Tubercle Bacilli in Primates
- (2010) Noton K. Dutta et al. JOURNAL OF INFECTIOUS DISEASES
- Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects
- (2009) A. M. Ginsberg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Assessment of the Effects of the Nitroimidazo-Oxazine PA-824 on Renal Function in Healthy Subjects
- (2009) A. M. Ginsberg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents
- (2008) J. G. Hurdle et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
- (2008) R. Singh et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started